BridgeBio

BridgeBio specializes in creating transformative medicines aimed at treating genetic diseases and cancers that have clear genetic drivers. The company employs a decentralized corporate structure, which aids in increasing the efficiency and speed of its drug development processes. BridgeBio has a broad clinical development presence, conducting trials in over 25 countries across five different therapeutic areas. It has successfully commercialized products such as NULIBRY (fosdenopterin) for MoCD Type A and TRUSELTIQ (infigratinib) for FGFR-driven cholangiocarcinoma. Operating under a hub-and-spoke model, BridgeBio’s affiliate companies each focus on developing therapies for specific diseases. The company’s innovative drug engineering platform includes technologies like molecular dynamics assisted chemistry and gene therapy, which are integral to its development strategy. BridgeBio is committed to patient-centric approaches in both clinical and regulatory strategies to ensure rapid and efficient treatment development. Additionally, the company is expanding its capabilities to deliver genetic medicines globally, which includes setting up Early Access Programs (EAP) and patient assistance programs. To support these initiatives, BridgeBio has raised significant capital, underpinning its efforts to develop and launch new genetic medicines.